Zonagen Announces U.S. IND For The Study Of Proellex(TM) In The Treatment Of Uterine Fibroids Has Become Effective

Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZONA) today announced that the Company’s IND for the U.S. study of its drug Proellex(TM) has become effective on December 14, 2005. The study will enroll 150 patients at up to 20 clinical sites in the United States.